Supercharged immune cells take on tough lymphoma
NCT ID NCT06120166
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests a new kind of CAR-T cell therapy, called Meta10-19, for people with diffuse large B-cell lymphoma that has come back or not responded to treatment. The cells are 'metabolically armed' to give them extra energy to fight cancer. The study will enroll 18 adults to find the safest dose and see if the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metabolically armed CD19 CAR-T cells (Meta10-19)
What this could lead to
If it works, this could point toward a more effective treatment for hard-to-treat lymphoma by boosting the energy of cancer-fighting immune cells.
What could go wrong
This is a very early, small trial (18 people) testing safety and dosing first. The approach may not work or could cause severe side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of medical college of zhejiang university
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact